
Professor Angus Dalgliesh graduated from University College Hospital, London and obtained an MBBS with an intercalated BSc Hons in Anatomy under Professor J. J. Young, FRS.
He specialised in Oncology at the Royal Brisbane Hospital, Mater and Chermside Hospitals in Brisbane before moving to the Ludwig Institute in Sydney at the Royal Prince Alfred Hospital.
After completing his training, he returned to the UK in 1984 to work as a Clinical Research Fellow with Professor Robin Weiss FRS, who was then the Director of the Institute of Cancer Research, and later worked in an honorary clinical position at the Royal Marsden Hospital with Dr Wiltshore. In 1986, Professor Dalgliesh was appointed MRC Clinical Scientist and honorary Consultant in General Medicine, Immunology and Oncology at the Clinical Research Centre at Northwick Park Hospital.
In 1991, Professor Dalgliesh was made Foundation Chair of Oncology at St. George's University of London and NHS Hospital and developed an interest in the immune system to treat cancer. He had already gained previous experience in studies using high dose IL-2 and Interferon and subsequently developed an interest in the potential of vaccines to treat cancer. In 1997 he founded Onyvax Ltd, a privately funded company dedicated to the development of cancer vaccines. Dalgleish is now an Emeritus Professor of Oncology at City St. George’s, University of London.
Professor Dalgliesh has held grants from all the major funding agencies and is on the Grant Committee for Cancer Projects at the European Commission. He has published over 500 peer reviewed publications and has co-edited 5 medical text books, contributing towards over 40 chapters.